Let’s get down to it: why should investors consider pharma stocks? Primarily, it comes down to the permanence of the underlying narrative. So long as humans are afflicted by various diseases, there will be a need for advanced pharmaceutical solutions. Therefore, money has been flowing into the broader biotechnology space and that will probably not fade anytime soon.
The second reason? Pure numbers. According to Grand View Research, the global biotech market reached a valuation of $1.55 trillion last year .
Between 2024 and 2030, analysts project that the sector will expand by a compound annual growth rate (CAGR) of 13.96%. At the culmination point, the ecosystem could be worth $3.
88 trillion. That’s a good enough reason right there. Plus, as an American investor, you’re in luck.
Just the U.S. sector itself reached a valuation of $246.
18 billion last year . By 2033, the domestic space could be worth $763.82 billion.
On that note, below are compelling pharma stocks to consider. Vertex Pharmaceuticals (VRTX) Based in Boston, Massachusetts, Vertex Pharmaceuticals (NASDAQ: VRTX ) engages in the development and commercialization of therapies for treating cystic fibrosis. It also features partnerships with advanced biotech firms such as Crispr Therapeutics (NASDAQ: CRSP ) – which is one of the top pharma stocks in its own right – to forward innovative healthcare solutions.
Financially, Vertex is notable for generating consistently solid performances. During the past four q.
